Cargando…
Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer
BACKGROUND: Platinum‐based chemotherapy is the standard first‐line treatment for patients with advanced pan‐negative non‐squamous (non‐Sq) non‐small cell lung cancer (NSCLC). However, it is unknown which chemotherapy regimen confers the greatest benefit in such patients. This study explored which ch...
Autores principales: | Xu, Haiyan, Xu, Fei, Zhu, Wenjie, Ying, Jianming, Wang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068426/ https://www.ncbi.nlm.nih.gov/pubmed/29917332 http://dx.doi.org/10.1111/1759-7714.12777 |
Ejemplares similares
-
Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020) -
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
por: Ricciardi, Serena, et al.
Publicado: (2009) -
Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020) -
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017) -
Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)